The heart in sarcoidosis

Jump to navigation Jump to search
The heart in sarcoidosis
The heart in sarcoidosis: Moderately dilated left ventricle.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

WikiDoc Resources for The heart in sarcoidosis

Articles

Most recent articles on The heart in sarcoidosis

Most cited articles on The heart in sarcoidosis

Review articles on The heart in sarcoidosis

Articles on The heart in sarcoidosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on The heart in sarcoidosis

Images of The heart in sarcoidosis

Photos of The heart in sarcoidosis

Podcasts & MP3s on The heart in sarcoidosis

Videos on The heart in sarcoidosis

Evidence Based Medicine

Cochrane Collaboration on The heart in sarcoidosis

Bandolier on The heart in sarcoidosis

TRIP on The heart in sarcoidosis

Clinical Trials

Ongoing Trials on The heart in sarcoidosis at Clinical Trials.gov

Trial results on The heart in sarcoidosis

Clinical Trials on The heart in sarcoidosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on The heart in sarcoidosis

NICE Guidance on The heart in sarcoidosis

NHS PRODIGY Guidance

FDA on The heart in sarcoidosis

CDC on The heart in sarcoidosis

Books

Books on The heart in sarcoidosis

News

The heart in sarcoidosis in the news

Be alerted to news on The heart in sarcoidosis

News trends on The heart in sarcoidosis

Commentary

Blogs on The heart in sarcoidosis

Definitions

Definitions of The heart in sarcoidosis

Patient Resources / Community

Patient resources on The heart in sarcoidosis

Discussion groups on The heart in sarcoidosis

Patient Handouts on The heart in sarcoidosis

Directions to Hospitals Treating The heart in sarcoidosis

Risk calculators and risk factors for The heart in sarcoidosis

Healthcare Provider Resources

Symptoms of The heart in sarcoidosis

Causes & Risk Factors for The heart in sarcoidosis

Diagnostic studies for The heart in sarcoidosis

Treatment of The heart in sarcoidosis

Continuing Medical Education (CME)

CME Programs on The heart in sarcoidosis

International

The heart in sarcoidosis en Espanol

The heart in sarcoidosis en Francais

Business

The heart in sarcoidosis in the Marketplace

Patents on The heart in sarcoidosis

Experimental / Informatics

List of terms related to The heart in sarcoidosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor: Cafer Zorkun, M.D., Ph.D. [2] ; Huda A. Karman, M.D.

Keywords: cardiac sarcoidosis, sarcoidosis cordis, sarcoid heart

Overview

Pericarditis as a manifestation of sarcoidosis has been frequently described and necropsy studies have documented cardiac involvement in 27% of patients, but clinically significant pericarditis is uncommon. In addition, sarcoidosis has been rarely documented in children. The granulomatous infiltrative disease of the myocardium is often asymptomatic, but can cause arrhythmias, conduction disease and, rarely, otherwise unexplained congestive heart failure. Early diagnosis can be very important because it's generally believed aggressive steroid treatment may decrease mortality. Granulomatous infiltration may be patchy, with a predilection toward involvement of the left ventricle, particularly the upper septal area. This distribution influences the likelihood of obtaining a diagnostic right sided endomyocardial biopsy. Use of gallium or thallium imaging may be helpful in determining the need for and duration of immunosuppressive therapy, but this approach has not been proved in any formal trial[1] [2][3] [4]. Sarcoid dilated cardiomyopathy may be difficult to distinguish from idiopathic cardiomyopathy or occasionally from giant cell myocarditis. Conduction disease is more common than pump dysfunction in patients with sarcoidosis. Biopsy may help distinguish sarcoidosis from idiopathic or giant cell myocarditis, but the diagnostic yield of endomyocardial biopsy is low. Active sarcoidosis is generally believed to be steroid responsive. However, myocardial involvement with sarcoid can result in large patches of fibrotic scar that may be arrhythmogenic but no longer respond to steroids. Scar is often significantly underestimated by imaging studies and biopsy. Pulmonary artery hypertension and cor pulmonale can occur in sarcoidosis, generally as a result of pulmonary fibrosis.Systemic vasculitis is an uncommon complication of sarcoidosis. Its prevalence remains unknown. Sarcoid vasculitis can affect small to large caliber vessels, including the aorta. The latter presentation can be easily confused with Takayasu arteritis. African American patients appear predisposed to developing large vessel involvement. [5] [6] [7] [8] [9]

Historical perspective

  • In 1869 Jonathan Hutchinson described the first case of cutaneous sarcoid [10]
  • In 1899 the disease was named by Boeck, a Norwegian dermatologist, who thought that the nodular skin lesions of epithelioid cells resemble sarcoma cells and descried them as sarcoid
  • In 1929, Bernstein was the first to recognize cardiac involvement in a patient with systemic sarcoidosis
  • In 1952, Longcope and Freiman were the first to describe myocardial involvement in 20% of 92 necropsied cases of sarcoidosis

Pathophysiology

Differentiating Cardiac sarcoidosis from Other Diseases

Cardiac sarcoidosis must be differentiated from other diseases such as cardiac amyloidosis


Disease Clinical manifistations Diagnosis Histopathology Prognosis
Cardiac sarcoidosis[14][15][16][17][18]
  • Depends on the site and extent of the granulomatous inflammation
  • Can range between asymptomatic conduction abnormalities to fatal ventricular arrhythmias
  • The most common finding is complete heart block, which is documented in 23-30% of patients with clinically evident cardiac sarcoidosis
  • First degree heart block
  • Bundle branch block
  • (Scar tissue/granuloma involve the basal septum, or the nodal artery and cause ischemia in the conduction system)
  • Re‐entrant tachyarrhythmias
  • Ventricular tachycardia (VT) is the most frequent arrhythmia with incidence of 23%
  • Sudden death due to arrhythmia usually is the terminal event
  • Supraventricular arrhythmias, less common, result of atrial dilatation and/or pulmonary involvement rather than the result of atrial granulomas
  • Congestive heart failure, the second most frequent cause of death, after sudden death. As a result of:
    • Widespread infiltration of the myocardium
    • Ventricular aneurysms
    • Rhythm disturbances
    • Cor pulmonale caused by pulmonary hypertension
    • Valvar regurgitation,
    • A combination of previous processes
  • Others:
    • Chest pain, electrocardiographic changes that may mimic transmural myocardial infarction
    • Pericardial abnormalities such as pericardial effusion, constrictive pericarditis, or even tamponade.
    • Pericardial effusions are not uncommon but rarely tend to tamponade
  • Japanese Ministry of Health and Welfare created guidelines to diagnose cardiac sarcoidosis:
  • Histologic:
  • Epithelioid non caseating granuloma
  • Clinical:
  • Complete right bundle branch block, left axis deviation, atrioventricular block, VT, premature ventricular contraction (⩾Lown 2), or abnormal Q or ST‐T change on the ECG or ambulatory ECG
  • Samples of myocardium with sarcoidosis shows the following:
  • Non‐caseating, multinucleated giant cell granuloma in the subendocardium
  • Trichrome stain can show a dense band of collagen fibers, encasing aggregate of granulomas and inflammatory cells
  • The prognosis of cardiac sarcoidosis is not well defined
  • Early necropsy series studies showed that in most patients with symptomatic cardiac sarcoidosis, survival was about two years
  • later studies showed better outcome where five year survival was 40–60%
  • It is unclear if this improvement in prognosis is a result of lead time bias or translates a milder cardiac sarcoidosis form v versus early introduction of corticosteroid therapy
  • Independent mortality predictors are:
  • New York Heart Association (NYHA) functional class
  • left ventricular end-diastolic diameter
  • Sustained VT
  • Greater survivals rates are in patients with preserved left ventricular function and good NYHA functional class
Cardiac amyloidosis

Epidemiology and Demographics

  • Sarcoidosis granuloma formation involves most commonly the lungs[19]


Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Cardiac MRI

Common MRI findings in patients with cardiac sarcoidosis include:


Treatment

References

  1. Braunwald's Heart Disease 8th Ed, 2007, Libby P
  2. "Sarcoidosis: eMedicine Pediatrics: General Medicine".
  3. Mayo Clinic Cardiology, Concise Textbook, 3rd edition, 2007
  4. Hurst's The Heart, Fuster V, 11th (printed) and 12th (online) editions, 2004-2008
  5. Harris: Kelley's Textbook of Rheumatology, 7th ed. 2005
  6. Robbins and Cotran PATHOLOGIC BASIS OF DISEASE, 7th Edition, 2005
  7. Washington Manual of Medical Therapeutics, The, 32nd Edition, 2007
  8. Cecil Textbook of Medicine, 23rd Edition, 2007
  9. Harrison's Principals of Internal Medicine, 16th Edition, 2005
  10. Doughan AR, Williams BR (2006). "Cardiac sarcoidosis". Heart. 92 (2): 282–8. doi:10.1136/hrt.2005.080481. PMC 1860791. PMID 16415205.
  11. 11.0 11.1 11.2 Roberts WC, McAllister HA, Ferrans VJ (1977). "Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11)". Am J Med. 63 (1): 86–108. doi:10.1016/0002-9343(77)90121-8. PMID 327806.
  12. 12.0 12.1 Schoppet M, Pankuweit S, Maisch B (2003). "Cardiac sarcoidosis: cytokine patterns in the course of the disease". Arch Pathol Lab Med. 127 (9): 1207–10. doi:10.1043/1543-2165(2003)127<1207:CSCPIT>2.0.CO;2. PMID 12946220.
  13. FERRANS VJ, HIBBS RG, BLACK WC, WALSH JJ, BURCH GE (1965). "MYOCARDIAL DEGENERATION IN CARDIAC SARCOIDOSIS: HISTOCHEMICAL AND ELECTRON MICROSCOPIC STUDIES". Am Heart J. 69: 159–72. doi:10.1016/0002-8703(65)90033-5. PMID 14256691.
  14. Roberts WC, McAllister HA, Ferrans VJ (1977). "Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11)". Am J Med. 63 (1): 86–108. doi:10.1016/0002-9343(77)90121-8. PMID 327806.
  15. Sekiguchi M, Numao Y, Imai M, Furuie T, Mikami R (1980). "Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis". Jpn Circ J. 44 (4): 249–63. doi:10.1253/jcj.44.249. PMID 7373823.
  16. Doughan AR, Williams BR (2006). "Cardiac sarcoidosis". Heart. 92 (2): 282–8. doi:10.1136/hrt.2005.080481. PMC 1860791. PMID 16415205.
  17. FERRANS VJ, HIBBS RG, BLACK WC, WALSH JJ, BURCH GE (1965). "MYOCARDIAL DEGENERATION IN CARDIAC SARCOIDOSIS: HISTOCHEMICAL AND ELECTRON MICROSCOPIC STUDIES". Am Heart J. 69: 159–72. doi:10.1016/0002-8703(65)90033-5. PMID 14256691.
  18. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T; et al. (2001). "Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone". Am J Cardiol. 88 (9): 1006–10. doi:10.1016/s0002-9149(01)01978-6. PMID 11703997.
  19. Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC (1997). "Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization". Am J Epidemiol. 145 (3): 234–41. doi:10.1093/oxfordjournals.aje.a009096. PMID 9012596.


Template:WikiDoc Sources